Media headlines about InVitae (NYSE:NVTA) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. InVitae earned a coverage optimism score of 0.06 on Accern’s scale. Accern also assigned headlines about the medical research company an impact score of 47.7123418409052 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the news headlines that may have effected Accern Sentiment Analysis’s analysis:
- Vamping Three Stocks: Invitae Corporation (NYSE:NVTA), Hennessy Capital Acquisition Corp. III (:HCAC), Xerium … (thestreetpoint.com)
- Analysts Insights on Invitae Corp (NVTA) (emnnews.com)
- Is Momentum Building For Invitae Corp (NVTA)? Chikou Jumps Above Tenkan (zeelandpress.com)
- Short-Term Picks To Give You An Edge: Invitae Corporation (NVTA), Corcept Therapeutics Incorporated (CORT) (nmsunews.com)
- Invitae continues pre-equity offering up move; shares ahead 4% (seekingalpha.com)
Shares of NYSE:NVTA opened at $14.52 on Wednesday. The company has a debt-to-equity ratio of 0.42, a current ratio of 3.75 and a quick ratio of 3.75. InVitae has a 12-month low of $4.35 and a 12-month high of $15.48.
InVitae (NYSE:NVTA) last issued its quarterly earnings results on Tuesday, August 7th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.07. InVitae had a negative return on equity of 111.27% and a negative net margin of 125.03%. The firm had revenue of $37.31 million for the quarter, compared to analyst estimates of $30.70 million. equities research analysts predict that InVitae will post -2.01 earnings per share for the current fiscal year.
NVTA has been the topic of a number of analyst reports. Zacks Investment Research lowered InVitae from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 15th. ValuEngine raised InVitae from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, August 29th. One research analyst has rated the stock with a sell rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $11.00.
InVitae Company Profile
Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. The company's tests include multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders, and other hereditary conditions; proactive health and wellness screening; and preimplantation embryo testing and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders.
Featured Article: Diversification in Investing
Receive News & Ratings for InVitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae and related companies with MarketBeat.com's FREE daily email newsletter.